Ventana Biotech Inc
PINK SHEETS : VNTA

Ventana Biotech Inc

August 03, 2009 21:38 ET

Ventana Appoints Vijay Guptha to Scientific Advisory Board

LONDON, UNITED KINGDOM--(Marketwire - Aug. 3, 2009) - Ventana Biotech Inc ("Ventana") (PINK SHEETS:VNTA), a biotechnology company that develops anti-obesity solutions, today announced its appointment of Vijay Guptha, PhD, to its Advisory Board.

Mr. Guptha will contribute his expertise and pharmaceutical experience to Ventana's business of sourcing and analyzing new anti-obesity drug targets, and identifying lucrative distribution channels for its patents.

Janne Christensen, President of Ventana, said, "We are delighted to have Dr. Guptha join our Advisory Board. He is an esteemed scholar, experienced pharmaceutical research professional and a respected advisor to numerous companies around the globe."

Mr. Guptha completed his biology and medical degrees at the University of Birmingham, England, and his PhD at the Stanford School of Medicine. His work experience includes research positions at SmithKline Beecham, and decades of work for large and small British and American pharmaceutical companies, with a specialization in obesity and Type 2 Diabetes research and development.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic anti-obesity drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative anti-obesity treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

FORWARD-LOOKING STATEMENTS:

Statements about Ventana's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. Ventana's actual results could differ materially from expected results. Ventana does not undertake any obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this objective; Ventana will appropriately inform the public.

For more information about Ventana Biotech Inc please contact investor@ventanabiotech.com.

Contact Information

  • Ventana Biotech Inc
    Janne Christensen, CEO
    BCB 1 Bachstrasse
    Butschwil CH-9606
    Switzerland
    +44 7930 732 426